Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Preventing Dementia

Preventing Dementia Opinion Editorial Neurology, Royal Melbourne Hospital at University non–image-forming vision. Nature. 2008;453 11. Minden SL, Frankel D, Hadden L, Perloffp J, of Melbourne, Grattan Street, Parkville, Melbourne, (7191):102-105. Srinath KP, Hoaglin DC. The Sonya Slifka Victoria 3050, Australia (obw@unimelb.edu.au). Longitudinal Multiple Sclerosis Study: methods and 6. Ruby NF, Brennan TJ, Xie X, et al. Role of sample characteristics. Mult Scler. 2006;12(1):24-38. Published Online: January 30, 2017. melanopsin in circadian responses to light. Science. doi:10.1001/jamaneurol.2016.5385 2002;298(5601):2211-2213. 12. Frohman E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Conflict of Interest Disclosures: None reported. 7. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller Neurol. 2006;5(10):853-863. A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci. 2012;314 13. Meltzer E, Sguigna PV, Subei A, et al. Retinal REFERENCES (1-2):37-40. architecture and melanopsin-mediated pupillary 1. Campbell JD, Ghushchyan V, Brett McQueen R, response characteristics: a putative 8. Gooley JJ, Lu J, Chou TC, Scammell TE, Saper CB. et al. Burden of multiple sclerosis on direct, indirect pathophysiologic signature for the Melanopsin in cells of origin of the costs and quality of life: National US estimates. Mult retino-hypothalamic tract in multiple sclerosis retinohypothalamic tract. Nat http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Preventing Dementia

DeKosky, Steven T.; Schneider, Lon S.
JAMA Neurology , Volume 74 (5) – May 20, 2017
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/preventing-dementia-UvcXtCIcpB
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2017.0045
pmid
28319236
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial Neurology, Royal Melbourne Hospital at University non–image-forming vision. Nature. 2008;453 11. Minden SL, Frankel D, Hadden L, Perloffp J, of Melbourne, Grattan Street, Parkville, Melbourne, (7191):102-105. Srinath KP, Hoaglin DC. The Sonya Slifka Victoria 3050, Australia (obw@unimelb.edu.au). Longitudinal Multiple Sclerosis Study: methods and 6. Ruby NF, Brennan TJ, Xie X, et al. Role of sample characteristics. Mult Scler. 2006;12(1):24-38. Published Online: January 30, 2017. melanopsin in circadian responses to light. Science. doi:10.1001/jamaneurol.2016.5385 2002;298(5601):2211-2213. 12. Frohman E, Costello F, Zivadinov R, et al. Optical coherence tomography in multiple sclerosis. Lancet Conflict of Interest Disclosures: None reported. 7. Melamud L, Golan D, Luboshitzky R, Lavi I, Miller Neurol. 2006;5(10):853-863. A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci. 2012;314 13. Meltzer E, Sguigna PV, Subei A, et al. Retinal REFERENCES (1-2):37-40. architecture and melanopsin-mediated pupillary 1. Campbell JD, Ghushchyan V, Brett McQueen R, response characteristics: a putative 8. Gooley JJ, Lu J, Chou TC, Scammell TE, Saper CB. et al. Burden of multiple sclerosis on direct, indirect pathophysiologic signature for the Melanopsin in cells of origin of the costs and quality of life: National US estimates. Mult retino-hypothalamic tract in multiple sclerosis retinohypothalamic tract. Nat

Journal

JAMA Neurology – American Medical Association

Published: May 20, 2017

References

  • Vitamin E and donepezil for the treatment of mild cognitive impairment
    Petersen, RC; Thomas, RG; Grundman, M
  • The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    Albert, MS; DeKosky, ST; Dickson, D
  • Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
    Sperling, RA; Aisen, PS; Beckett, LA
  • Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees
    Klunk, WE; Price, JC; Mathis, CA
  • Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study
    Villemagne, VL; Burnham, S; Bourgeat, P
  • Regulatory innovation and drug development for early-stage Alzheimer’s disease
    Kozauer, N; Katz, R
  • Ginkgo biloba for prevention of dementia: a randomized controlled trial
    DeKosky, ST; Williamson, JD; Fitzpatrick, AL
  • Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial
    Vellas, B; Coley, N; Ousset, P-J
  • Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
    Lyketsos, CG; Breitner, JC; Green, RC
  • Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial
    Shumaker, SA; Legault, C; Rapp, SR
  • Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    Shepherd, J; Blauw, GJ; Murphy, MB
  • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
  • Association of antioxidant supplement use and dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium trial (PREADViSE)
    Kryscio, RJ; Abner, EL; Caban-Holt, A
  • A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: the PREADViSE Trial
    Kryscio, RJ; Abner, EL; Schmitt, FA
  • National estimates of the prevalence of Alzheimer’s disease in the United States
    Brookmeyer, R; Evans, DA; Hebert, L
  • Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial
    Moll van Charante, EP; Richard, E; Eurelings, LS